PlainRecalls
FDA Drug Moderate Class II Ongoing

Rizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-262-18

Reported: July 23, 2025 Initiated: July 9, 2025 #D-0534-2025

Product Description

Rizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-262-18

Reason for Recall

CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Details

Recalling Firm
Ascend Laboratories, LLC
Units Affected
N/A
Distribution
US Nationwide.
Location
Bedminster, NJ

Frequently Asked Questions

What product was recalled?
Rizatriptan Benzoate Tablets, USP, 10 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories LLC, Parsippany, NJ 07054, NDC 67877-262-18. Recalled by Ascend Laboratories, LLC. Units affected: N/A.
Why was this product recalled?
CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 23, 2025. Severity: Moderate. Recall number: D-0534-2025.